Last reviewed · How we verify
prednisolon
At a glance
| Generic name | prednisolon |
|---|---|
| Also known as | Decortin, steroid withdrawal |
| Sponsor | Hannover Medical School |
| Target | Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acquired thrombocytopenia
- Acute lymphoid leukemia
- Adrenal cortical hypofunction
- Adrenogenital disorder
- Allergic bronchopulmonary aspergillosis
- Allergic conjunctivitis
- Allergic rhinitis
- Angioedema
- Ankylosing spondylitis
- Articular gout
- Aspiration pneumonitis
- Asthma
- Atopic dermatitis
- Autoimmune disease
- Autoimmune hemolytic anemia
- Bacterial conjunctivitis
- Bacterial keratitis
- Berylliosis
- Blepharoconjunctivitis
- Bursitis
Common side effects
- Weight gain
- Increased appetite
- Fluid retention
- Hypertension
- Nausea
- Malaise
- Facial erythema
- Increased sweating
- Edema
- Headache
- Muscle weakness
- Hirsutism
Serious adverse events
- Peptic ulcer with possible perforation and hemorrhage
- Congestive heart failure
- Aseptic necrosis of femoral and humeral heads
- Osteoporosis with pathologic fracture
- Increased intracranial pressure with papilledema (pseudotumor cerebri)
- Glaucoma
- Posterior subcapsular cataracts
- Pancreatitis
- Convulsions
- Tendon rupture
Key clinical trials
- Treat-to-target Prednisolon Taper in Patients With Polymyalgia Rheumatica (NA)
- Repeated GON Injections in CCH (PHASE3)
- Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome (PHASE3)
- Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis (PHASE2)
- A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis (PHASE2)
- Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
- Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis (PHASE2)
- The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prednisolon CI brief — competitive landscape report
- prednisolon updates RSS · CI watch RSS
- Hannover Medical School portfolio CI